Journal of nuclear medicine : official publication, Society of Nuclear Medicine最新文献

{"title":"Kenneth A. Krohn, PhD, 1945-2024.","authors":"Janet Eary, Jeanne Link, David Mankoff, David Vera, Tom Ruth","doi":"10.2967/jnumed.124.269449","DOIUrl":"https://doi.org/10.2967/jnumed.124.269449","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On Facilitating the End of the Linear No-Threshold Era.","authors":"Eduardo Galiano","doi":"10.2967/jnumed.124.269042","DOIUrl":"https://doi.org/10.2967/jnumed.124.269042","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Side-by-Side Comparison of the In Vivo Performance of [²¹²Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds.","authors":"Amal Saidi, Tania A Stallons, Amy G Wong, Aaron T Schatzmann, Ugur Soysal, Julien J Torgue","doi":"10.2967/jnumed.124.268345","DOIUrl":"https://doi.org/10.2967/jnumed.124.268345","url":null,"abstract":"<p><p>There are numerous versions of octreotide and octreotate, including DOTAMTATE, DOTATATE, JR11, and lead-specific chelator (PSC)-PEG2-TOC. These peptides, which can be either analogs or antagonists, are used in nuclear medicine for diagnostic imaging or targeted radionuclide therapy of neuroendocrine tumors that are positive for somatostatin receptors (SSTRs). Despite their structural and targeting similarities, they have distinct properties and clinical uses. We aimed to perform an extensive preclinical comparison of all these somatostatin analogs with ²¹²Pb, directly studying their pharmacokinetic properties in tumors overexpressing SSTR2. <b>Methods:</b> All SSTR2 analogs were manufactured with the DOTAM, PSC, or DOTA chelators for appropriate comparison after radiolabeling with ²¹²Pb. Chelation, quantification, and pharmacokinetics were compared side by side in AR42J-tumor-bearing animals. <b>Results:</b> These findings highlight the superior chelation efficiency and faster kinetics of DOTAM and then DOTA compared with the PSC. We also discovered a superior tumor-to-kidney area under the curve ratio for [²¹²Pb]Pb-DOTAMTATE over other SSTR2-targeting peptides when radiolabeled with ²¹²Pb. <b>Conclusion:</b> Taken together, the results indicates that [²¹²Pb]Pb-DOTAMTATE has favorable tumor retention and a more favorable dosimetry profile, which is crucial for targeted α-therapy in treating SSTR2-positive neuroendocrine tumors.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Tomorrow's Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development.","authors":"Jacob S Van Naarden, Ken Herrmann, Johannes Czernin","doi":"10.2967/jnumed.124.269354","DOIUrl":"https://doi.org/10.2967/jnumed.124.269354","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison Between Brain and Cerebellar Autoradiography Using [¹⁸F]Flortaucipir, [¹⁸F]MK6240, and [¹⁸F]PI2620 in Postmortem Human Brain Tissue.","authors":"Antonio Aliaga, Joseph Therriault, Kely Monica Quispialaya, Arturo Aliaga, Robert Hopewell, Nesrine Rahmouni, Arthur C Macedo, Peter Kunach, Jean-Paul Soucy, Gassan Massarweh, Aida Abreu Diaz, Tharick A Pascoal, Andreia Rocha, Marie-Christine Guiot, Luiza S Machado, Marco Antônio De Bastiani, Débora Guerini de Souza, Diogo O Souza, Serge Gauthier, Eduardo R Zimmer, Pedro Rosa-Neto","doi":"10.2967/jnumed.124.267539","DOIUrl":"10.2967/jnumed.124.267539","url":null,"abstract":"<p><p>Our objective was to evaluate the in vitro binding properties of [¹⁸F]flortaucipir, 6-(fluoro-¹⁸F)-3-(1<i>H</i>-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([¹⁸F]MK6240), and 2-(2-([¹⁸F]fluoro)pyridin-4-yl)-9<i>H</i>-pyrrolo[2,3-b:4,5c']dipyridine ([¹⁸F]PI2620) head-to-head in postmortem human brain tissue. <b>Methods:</b> Autoradiography was used to assess uptake of [¹⁸F]flortaucipir, [¹⁸F]MK6240, and [¹⁸F]PI2620 in control and Alzheimer disease (AD) autopsy-confirmed brain tissues. The study focused on the analysis of the prefrontal cortex, hippocampus, and cerebellum sections in 12 controls and 12 AD cases, as well as whole-brain hemisphere in 1 control and 1 AD sample, for each radiotracer. The binding values of [¹⁸F]flortaucipir, [¹⁸F]MK6240, and [¹⁸F]PI2620 were calculated from regions of interest manually drawn in the prefrontal, hippocampal, and cerebellar cortices. <b>Results:</b> For all 3 radioligands investigated, we observed significant tracer binding differences between control and AD tissues in the whole-brain hemisphere, prefrontal cortex, and hippocampus but not in the cerebellar cortex. [¹⁸F]MK6240 and [¹⁸F]PI2620 had higher effect sizes to differentiate control and AD cases than did [¹⁸F]flortaucipir. Bland-Altman analyses revealed strong correlations between [¹⁸F]MK6240, [¹⁸F]PI2620, and [¹⁸F]flortaucipir, with the highest agreement found for [¹⁸F]MK6240 versus [¹⁸F]PI2620. <b>Conclusion:</b> The 3 radioligands showed comparable diagnostic properties to assess tau aggregates in vitro. Binding to AD brain tissues was higher for [¹⁸F]MK6240 and [¹⁸F]PI2620 than for [¹⁸F]flortaucipir. Additionally, [¹⁸F]MK6240 and [¹⁸F]PI2620 had greater selectivity, displaying decreased uptake in control brain tissue compared with [¹⁸F]flortaucipir. These results might provide insights on ongoing initiatives to create a universal scale for tau imaging studies.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"123-129"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspective on Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery.","authors":"Roberto C Delgado Bolton","doi":"10.2967/jnumed.124.268783","DOIUrl":"10.2967/jnumed.124.268783","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"73-74"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Theranostics for Meningioma on the Rise: New EANM/EANO/RANO/SNMMI Guidelines Pave the Way to Improved Patient Outcomes Using Radiolabeled Somatostatin Receptor Ligands.","authors":"Nathalie L Albert, Matthias Preusser, Norbert Galldiks, Jana Ivanidze","doi":"10.2967/jnumed.124.268314","DOIUrl":"10.2967/jnumed.124.268314","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"24-25"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solving Challenging Puzzles: Heather Jacene Talks with Johannes Czernin About Leadership in Clinical Nuclear Medicine and the SNMMI.","authors":"Heather Jacene, Johannes Czernin","doi":"10.2967/jnumed.124.269029","DOIUrl":"10.2967/jnumed.124.269029","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142690148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging of the Aging Human Brain.","authors":"Yan Zhong, Chentao Jin, Xiaofeng Dou, Rui Zhou, Mei Tian, Hong Zhang","doi":"10.2967/jnumed.124.268451","DOIUrl":"10.2967/jnumed.124.268451","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"12-13"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study.","authors":"Lyduine E Collij, Gérard N Bischof, Daniele Altomare, Ilse Bader, Mark Battle, David Vállez García, Isadora Lopes Alves, Robin Wolz, Rossella Gismondi, Andrew Stephens, Zuzana Walker, Philip Scheltens, Agneta Nordberg, Juan Domingo Gispert, Alexander Drzezga, Andrés Perissinotti, Silvia Morbelli, Christopher Buckley, Valentina Garibotto, Giovanni B Frisoni, Gill Farrar, Frederik Barkhof","doi":"10.2967/jnumed.124.268119","DOIUrl":"10.2967/jnumed.124.268119","url":null,"abstract":"<p><p>Several studies have demonstrated strong agreement between routine clinical visual assessment and quantification, suggesting that quantification approaches could support assessment by less experienced readers or in challenging cases. However, all studies to date have implemented a retrospective case collection, and challenging cases were generally underrepresented. <b>Methods:</b> We included all participants (<i>n</i> = 741) from the AMYPAD diagnostic and patient management study with available baseline amyloid PET quantification. Quantification was done with the PET-only AmyPype pipeline, providing global Centiloid and regional <i>z</i> scores. Visual assessment was performed by local readers for the entire cohort. From the total cohort, we selected a subsample of 85 cases for which the amyloid status based on the local reader's visual assessment and the Centiloid classification (cutoff = 21) was discordant or that were assessed with low confidence (i.e., ≤3 on a 5-point scale) by the local reader. In addition, concordant negative (<i>n</i> = 8) and positive (<i>n</i> = 8) scans across tracers were selected. In this sample (<i>n</i> = 101 cases; [¹⁸F]flutemetamol, <i>n</i> = 48; [¹⁸F]florbetaben, <i>n</i> = 53), the visual assessments and corresponding confidence by 5 certified independent central readers were captured before and after disclosure of the quantification results. <b>Results:</b> For the whole AMYPAD diagnostic and patient management study cohort, overall assessment by local readers highly agreed with Centiloid status (κ = 0.85, 92.3% agreement). This was consistently observed within disease stages (subjective cognitive decline-plus, κ = 0.82, 92.3% agreement; mild cognitive impairment, κ = 0.80, 89.8% agreement; dementia, κ = 0.87, 94.6% agreement). Across all central reader assessments in the challenging subsample, quantification of global Centiloid and regional <i>z</i> scores was considered supportive of visual reads in 70.3% and 49.3% of assessments, respectively. After disclosure of the quantitative results, we observed improvement in concordance across the 5 readers (baseline κ = 0.65, 65.3% agreement; κ after disclosure = 0.74, 73.3% agreement) and a significant increase in reader confidence (baseline mean (<i>M</i>) = 4.0 vs. <i>M</i> after disclosure = 4.34, Wilcoxon statistic (<i>W</i>) = 101,056, <i>P</i> < 0.001). <b>Conclusion:</b> In this clinical study enriched for challenging amyloid PET cases, we demonstrate the value of quantification to support visual assessment. After disclosure, both interreader agreement and confidence showed significant improvement. These results are important considering the arrival of antiamyloid therapies, which used the Centiloid metric for trial inclusion and target engagement. Moreover, quantification could support determination of amyloid-β status with high certainty, an important factor for treatment initiation.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"110-116"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}